ARTICLE | Clinical News
Remicade Phase III psoriasis data
March 4, 2006 1:38 AM UTC
Remicade infliximab from Johnson & Johnson (JNJ) and Schering-Plough (SGP) met the primary endpoint of PASI 75 at week 10 in the Phase III EXPRESS II trial to treat moderate to severe plaque psoriasis...